GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Net Interest Income

Aquestive Therapeutics (Aquestive Therapeutics) Net Interest Income : $-8.04 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Aquestive Therapeutics's net interest income for the three months ended in Mar. 2024 was $-3.87 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.04 Mil.

Aquestive Therapeutics Net Interest Income Historical Data

The historical data trend for Aquestive Therapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics Net Interest Income Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial -8.68 -12.89 -22.04 -12.34 8.86

Aquestive Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.03 -1.30 0.20 -3.07 -3.87

Aquestive Therapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquestive Therapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Net Interest Income
Comparable Companies
ETON EBS ESPR ELTP MRMD TKNO DRRX OPTN BGXX SCYX ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Website
https://www.aquestive.com
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki officer: SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung officer: SVP, Operations C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt officer: Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd officer: SVP-Operations/Value Delivery 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender officer: SVP, General Counsel 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber officer: SVP-Chief Strategy/Dev Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel director, officer: Chief Innovation/Tech Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr officer: Interim CFO
John T. Maxwell officer: SVP-Chief Financial Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall director, officer: President and CEO 30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta director C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154